Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.37 |
| ▸ | RHEB | Q15382 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748582 | 0.86 | EGLN1 (0.38) | EGLN1HRH4DHODH | |
| SCHEMBL17109180 | 0.76 | HRH4 (0.43) | EGLN1PIN1HRH4RHEBDHODH | |
| SCHEMBL12271513 | 0.76 | HRH4 (0.58) | EGLN1PIN1HRH4RHEBDHODH | |
| SCHEMBL17092653 | 0.73 | EGLN1 (0.55) | EGLN1PIN1HRH4RHEB | |
| SCHEMBL31024290 | 0.73 | RHEB (0.45) | EGLN1PIN1HRH4RHEBDHODH | |
| SCHEMBL3423120 | 0.71 | PIN1 (0.56) | EGLN1PIN1HRH4RHEB | |
| SCHEMBL31748505 | 0.70 | CBFB (0.33) | EGLN1 | |
| SCHEMBL31748611 | 0.70 | PSMB8 (0.41) | EGLN1DHODH | |
| SCHEMBL6988197 | 0.69 | EGLN1 (0.53) | EGLN1PIN1DHODH | |
| SCHEMBL3871577 | 0.67 | EGLN1 (0.55) | EGLN1PIN1HRH4RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | EGLN1 3554/4885PIN1 4098/4885HRH4 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.